Context: Denosumab, an inhibitor of receptor activator of nuclear factor k-B ligand, is an approved treatment of giant cell tumor of bone (GCTB) in adults and "skeletally mature" adolescents. Safety concerns include oversuppression of bone remodelling, with risk of osteonecrosis of the jaw (ONJ) and atypical femur fractures during treatment in adults and rebound hypercalcemia after treatment cessation in children. To date, ONJ has never been reported in children or adolescents.
resectable tumors require excision and reconstruction or even joint-sacrificing surgery given the predilection of the tumor for apophyseal locations (1) .
GCTB is characterized by the presence of multinucleated, osteoclast-like giant cells (2) . The neoplastic stromal cells express high concentrations of receptor activator of nuclear factor k-B ligand, which activates its receptor RANK on giant cells and their precursors (2) . Denosumab is a human monoclonal antibody that neutralizes the activity of nuclear factor k-B ligand and therefore suppresses osteolytic bone destruction in GCTB (3) . Greater than 90% elimination of giant cells after 25 week treatment with highdose denosumab (120 mg subcutaneously on days 1, 8, 15, and 28, and then every 4 weeks thereafter) has been reported (n = 20) (4) . Denosumab is approved by Food and Drug Administration and European Medicines Agency for the treatment of GCTB in adults and skeletally mature adolescents, when the tumor is deemed unresectable, requires morbid surgery, or in metastatic disease. However, uncertainties regarding treatment duration remain (5) .
The main safety concern of antiresorptive therapy relates to the oversuppression of bone remodeling. In adults, bisphosphonates have been implicated in the development of osteonecrosis of the jaw (ONJ) (6) and atypical femoral fractures (7) , which has led to restrictions in treatment duration. High-dose denosumab therapy also causes ONJ and atypical femoral fractures in 6% and 4%, respectively, of adults treated for GCTB (5) . Because of the potent and rapid on-off effects on osteoclastic bone resorption, rebound hypercalcemia following treatment discontinuation has emerged as a relatively new adverse event specific to denosumab (8) .
In children and adolescents with osteogenesis imperfecta and osteoporosis, prolonged or high-dose bisphosphonate therapy has been associated with iatrogenic osteopetrosis (9) and suspected atypical femoral fractures (10, 11) , but never with ONJ (12) or rebound hypercalcemia. To date, safety data for denosumab in adolescents are sparse because only 3.5% (n = 10 of 282) of patients in the GCTB safety trial were adolescents (age, 13 to 17 years) (3). Low-dose denosumab therapy (1 mg/kg 12-weekly over 48 weeks) was found to be safe in a small number (n = 10) of pediatric patients with osteogenesis imperfecta (13) . However, four cases of rebound hypercalcemia following cessation of denosumab (dose range, 0.5 mg/kg to 120 mg in GCTB) have been reported in children (age, 8 to 10 years), and attributed to their physiologically higher bone turnover (14) (15) (16) (17) . The safety of prolonged use of denosumab in adolescents remains unknown because of a dearth of longterm follow-up studies.
Case Descriptions
Individuals described here had a confirmed histological diagnosis of GCTB and received denosumab, 120 mg subcutaneously on days 1, 8, 15, and 28, and then every 4 weeks as part of a phase 2 clinical trial (18) . All patients received fixed doses irrespective of age or weight as per the protocol but for different durations. Patient demographics, disease specifications, treatment indications, dose and duration, and reason for treatment cessation are detailed in Table 1. Table 2 details the biochemical picture at presentation of rebound hypercalcemia and its management.
Patient 1

Diagnosis and initial management
A 15-year-old male with biopsy-proven GCTB of the sacrum received denosumab for unresectable, recurring tumor despite previous embolization and curettage. 
ONJ
In the fourth year of denosumab treatment (after 44 doses), the patient (then aged 19 years) underwent dental extraction for a chipped tooth sustained while playing football. The risk of developing ONJ was discussed and the patient was advised on dental hygiene and smoking cessation. Weighing up the risks of developing ONJ against recurrence of GCTB, denosumab was continued after ensuring complete healing of mucosa in the extraction socket with no exposed bone. Two months later, he presented with acute pain at the dental extraction site. ONJ stage two was diagnosed (Fig. 1A) as per the classification adopted by the American Association of Oral & Maxillofacial Surgeons (6) . Denosumab was stopped after a total of 46 doses (cumulative dose, 98 mg/kg). Swab of the affected area showed heavy growth of Streptococcus milleri and a moderate growth of a-hemolytic Streptococcus. The ONJ was initially managed conservatively (amoxicillin, metronidazole, and mouthwash) with poor healing, necessitating debridement and sequestrectomy of the exposed bone. A moderate amount of necrotic bone around the extraction socket of the left mandible was debrided with subsequent full recovery. Clear demarcation between necrotic and normal bone was noted at surgery.
Rebound hypercalcemia with acute kidney injury
Seven months after stopping denosumab, the patient presented with a 3-week history of nausea, vomiting, and generalized body pain. Investigations identified raised serum calcium (3.1 mmol/L) ( Fig. 2A) and creatinine, indicating acute kidney injury. Serum phosphate and alkaline phosphatase were normal, 25-hydroxy vitamin D was low, and parathyroid hormone appropriately suppressed (Table 2) , with normal thyroid function. A magnetic resonance imaging (MRI) scan and bone scintigraphy demonstrated no evidence of local or metastatic disease. C-terminal telopeptide of type I collagen was elevated [3.07 mg/L (normal range, 0.016 to 0.584)], confirming increased bone resorption and the diagnosis of rebound hypercalcemia secondary to denosumab discontinuation was made.
Management and progress
Hypercalcemia persisted despite hyperhydration (volume expansion) and resolution of the acute kidney injury. As bisphosphonates were considered contraindicated because of ONJ and renal failure, calcitonin (Table 2) was administered on day 0 (D0). Normocalcemia was only achieved following a second dose on D2 ( Fig. 2A) .
Despite compliance with high volume oral hydration at home, symptomatic hypercalcemia recurred on D19 and D33, requiring readmission for hyperhydration and calcitonin ( Fig. 2A) . On each rechallenge with calcitonin, control of hypercalcemia was more durable. Eighteen months after stopping denosumab, the patient remained normocalcemic on a high-volume oral fluid regimen, ONJ had healed, and there was no tumor recurrence.
Patient 2
Diagnosis and initial management A 14-year-old female with sacral GCTB received neoadjuvant treatment with denosumab because of the extent of the tumor. MRI scans showed a reduction in tumor volume after 12 doses and she underwent a partial sacrectomy; histology confirmed 50% loss of giant cells, in keeping with a response to denosumab. A further six doses of denosumab every 4 weeks postoperatively were administered, with a cumulative dose of 47 mg/kg. A full recovery was made, with resolution of the lower back pain noted on presentation and return to full weightbearing activities.
Rebound hypercalcemia with acute kidney injury Six months after the last dose of denosumab, the patient (aged 15.9 years) experienced increasing back pain, paraesthesia of her legs, and nausea. An MRI scan showed no evidence of recurrence or metastases. Investigations revealed marked hypercalcemia (serum calcium, 3.4 mmol/L) ( Fig. 2B) with acute kidney injury. Denosumab-induced rebound hypercalcemia was diagnosed following exclusion of other causes (i.e., hyperparathyroidism and thyrotoxicosis) ( Table 2 ). Her 25-hydroxy vitamin D levels were very low.
Management and progress
Hyperhydration (150% maintenance) was commenced and single dose of frusemide (1 mg/kg) was administered on D0 to induce calciuresis. Because continued hyperhydration over 5 days was unsuccessful in resolving the hypercalcemia, low-dose pamidronate (Table 2) was administered on D5 and D6 (Fig. 2B) . Calcium normalized on D7 and previously suppressed parathyroid hormone improved to 29 ng/L. A single dose of cholecalciferol (150,000 IU) followed by daily vitamin D (400 IU) and calcium supplements (1.2 g three times a day) were commenced. Symptomatic hypocalcemia nevertheless occurred, requiring one bolus dose of intravenous calcium, followed by oral calcium supplementation that was weaned over 4 weeks. Severe bone pain, initially managed with ibuprofen and morphine, responded very well to pamidronate. Serum calcium remains stable 1 year after pamidronate with no further episodes of rebound hypercalcemia. GCTB remains under remission.
Patient 3
Diagnosis and initial management
A 40-year-old male, with very large and vascular GCTB of the scapula, opted for denosumab treatment. Clinical and radiologic response to treatment was achieved and denosumab continued to avoid morbid surgical resection of the whole scapula. After 51 doses of denosumab therapy (cumulative dose, 51 mg/kg), the patient presented with bilateral thigh pain. Plain radiographs did not reveal any identifiable lesions; therefore, a single-photon emission computed tomography scan was undertaken that revealed increased tracer uptake on the medial cortex of both proximal femora, the area of clinical concern (Fig. 1B) . Because such femoral cortical stress reactions are associated with antiresorptive agents (7), denosumab therapy was stopped. Thigh pain settled with denosumab cessation and did not necessitate any treatment. 
Rebound hypercalcemia and acute kidney injury
The patient presented to the emergency department 5.5 months after denosumab cessation with drowsiness, polyuria, polydipsia, and vomiting. On presentation, hypercalcemia (serum calcium, 4.27 mmol/L) and acute kidney injury (Table 2 ) was diagnosed, which was managed with hyperhydration and ibandronate (Fig. 2C) . Parathyroid hormone was appropriately suppressed. The patient presented again on D33 with a further episode of hypercalcemia, which was managed with hyperhydration alone. At restaging, 7.5 months from stopping denosumab, a relatively small focal recurrence was identified relative to the overall dimensions of the initial tumor on MRI scan and was confirmed on biopsy. This has been managed by subtotal scapulectomy.
Discussion
Prolonged, potent antiresorptive therapy (including bisphosphonates and denosumab) in adults is associated with ONJ and atypical femoral fractures. To date, these serious adverse effects have not been reported in children and adolescents. Here we report a case of ONJ in an adolescent (patient 1) and femoral cortical stress reactions in a young adult (patient 3) receiving treatment with fixed high-dose denosumab for GCTB. The fact that these two patients and another adolescent also developed rebound hypercalcemia and acute kidney injury following treatment cessation raises serious safety questions. All patients were naïve to chemotherapy, radiotherapy, and bisphosphonates and had no evidence of metastatic disease, confirming the causative role of denosumab in these complications.
Antiresorptive therapy in children is generally considered safe. However, the case of a child who developed iatrogenic osteopetrosis with tubelike, dense metaphyses during prolonged, high-dose bisphosphonate therapy has raised safety concerns among pediatric bone specialists (9) . Side effects of standard-dose bisphosphonate therapy include typical metaphyseal sclerotic bands that are also seen in denosumab treatment (19) . Bisphosphonates have also been associated with suspected atypical femoral fractures in children (10, 11), although not confirmed in larger series (20, 21) . Several studies have assessed the risk of developing ONJ in bisphosphonate-treated children following dental treatment (22, 23) ; however, no cases have been reported so far.
Medication or antiresorptive agent-related ONJ (6) has been associated with risk factors such as smoking, old age, poor oral hygiene, invasive dental procedures, serious comorbidities, and concomitant treatments (18) . ONJ has been reported in nearly 6% of GCTB treated patients (5). Patient 1 developed ONJ following a dental extraction, a known major risk factor reported by 52% to 61% of adult ONJ patients, with greatest risk in those on intravenous bisphosphonates (6) . He was also a smoker and had poor dental hygiene and hence had several risk factors for developing ONJ.
The risk of ONJ in adults on antiresorptive treatment is dose-and duration-dependent (5). The fixed denosumab dose of 120 mg every 4 weeks is based on 90% suppression of urinary N-telopeptide normalized to urinary creatinine in adults (n = 373) with bone metastases from solid tumors (24) . Although no study to date has determined appropriate pediatric doses, these high doses were anticipated to be safe in adolescents weighing .45 kg with closed growth plates based on data extrapolated from adults with GCTB weighing as low as 38 kg (18) . However, bone metabolism in young people differs from adults and includes bone modeling and elongation, with bone accrual into their late 20s, long after closure of growth plates (25) . The teenage GCTB patients reported here, and those in other reports (14, 15) , indicate an urgent need to consider weight-based dosing and systematic safety studies. Although the rate and extent of urinary N-telopeptide normalized to urinary creatinine suppression are reported to remain constant at denosumab doses .0.3 mg/kg, the duration of maximum suppression increases with increasing doses (26, 27) . Moreover, denosumab displays a dose-proportional increase in exposure at doses .60 mg. Of note, the incidence of denosumab related ONJ in prostate cancer patients is reportedly higher in clinical practice (28) when compared with trials (29) (11.4% vs 2.3%, respectively). Hence, the clinical implications and safety of cumulative doses over a prolonged period require further studies (30) .
Patient 3 developed femoral cortical stress reactions in the proximal femur bilaterally. Atypical femoral fractures have been linked to denosumab (5). The incidence of femoral cortical stress reactions in metastatic bone disease patients receiving denosumab is reported to be ;4.5% (31) . Femoral cortical stress reaction is recognized as a prodrome of atypical femoral fracture (31) (32) (33) (34) . Unlike previous reports, patient 3 did not have osteoporosis or metastatic disease and was not exposed to bisphosphonates or corticosteroids, indicating the independent role of denosumab in the causation of femoral cortical stress reactions.
Hypocalcemia during denosumab treatment is well recognized as a sign of rapid suppression of bone remodeling (3); however, rebound hypercalcemia from rapid release of previously suppressed remodeling is less known and is therefore unmonitored. There are four reported cases of rebound hypercalcemia following denosumab cessation in children, occurring between 7 weeks to 5 months after treatment cessation. Two juvenile patients with GCTB received high-dose denosumab (14, 15) ; the third, a 9-year-old boy with fibrous dysplasia, received a starting denosumab dose of 1 mg/kg increasing up to 1.75 mg/kg with 0.25 mg/ kg dose increments every 3 months (16); and the fourth, an 8-year-old girl with Paget disease received 0.5 mg/kg (17) .
Rebound hypercalcemia is due to osteoclast overactivity after denosumab cessation and is thought to be a feature of skeletally immature children because of high bone turnover. In contrast, patient 3, aged 40, and another reported adult, aged 60, also experienced rebound hypercalcemia (8) , indicating that this side effect is not restricted to young patients. Although hypercalcemia can be a sign of tumor reactivation, there was no such evidence in our patients. Similar to previous reports (14, 15) , all of our patients had parathyroid hormone-independent hypercalcemia. Suppressed parathyroid hormone noted at presentation improved following treatment of hypercalcemia (patient 2).
There are no data on the incidence of rebound hypercalcemia and no monitoring or management guidelines. The mean half-life of denosumab after cessation is reported to be 29 days (range, 25 to 35 days) (27) . However, the clearance is likely to be longer in individuals with accumulated doses, hence the occurrence of rebound hypercalcemia as late as 7 months from treatment cessation. Possibly, the presence of vitamin D deficiency in patients 1 and 2 delayed their presentation. Hypercalcemia responded poorly to hydration alone, so patient 1 was managed with calcitonin in the setting of ONJ and renal failure, and patients 2 and 3 with low-dose pamidronate and ibandronate. A previous report described resistance to a combined use of calcitonin, pamidronate, and corticosteroids, necessitating the use of low-dose denosumab (15) . Although the prolonged antiresorptive action of bisphosphonates is an effective treatment of hypercalcemia in this setting, the presence of acute kidney injury increases the risk of bisphosphonate-induced renal failure. None of the patients reported here were monitored for rebound hypercalcemia and presented unwell and in pain, requiring extensive investigations to rule out other causes of hypercalcemia. The increasing use of denosumab necessitates monitoring and increased awareness among clinicians and patients.
Conclusions
The effect that denosumab has on GCTB size reduction is remarkable, but the necessity for high-dose, long-term antiresorptive therapy comes at the price of suppression of bone remodeling, which, in adults, includes the risk of ONJ and atypical femoral fractures. Denosumab, with its potent suppression-release effects, has introduced the additional complications of hypocalcemia at drug commencement and rebound hypercalcemia after discontinuation. This case of ONJ in an adolescent and the substantial morbidity from rebound hypercalcemia after treatment discontinuation in our young patients stresses the need to consider weight-adjusted dosing, frequency and duration of treatment, and developing tools to monitor treatment. A systematic monitoring of serum calcium and pain for a minimum of 7 months after treatment cessation should be adopted.
